<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref008">
 <label>8</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Armand</surname>
   <given-names>P</given-names>
  </name>, 
  <name>
   <surname>Shipp</surname>
   <given-names>MA</given-names>
  </name>, 
  <name>
   <surname>Ribrag</surname>
   <given-names>V</given-names>
  </name>, 
  <name>
   <surname>Michot</surname>
   <given-names>JM</given-names>
  </name>, 
  <name>
   <surname>Zinzani</surname>
   <given-names>PL</given-names>
  </name>, 
  <name>
   <surname>Kuruvilla</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure</article-title>. 
  <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. 
  <year>2016</year>;(
  <issue>31</issue>):
  <fpage>3733</fpage>â€“
  <lpage>9</lpage>. 
  <pub-id pub-id-type="doi">10.1200/JCO.2016.67.3467</pub-id> .
  <?supplied-pmid 27354476?>
  <pub-id pub-id-type="pmid">27354476</pub-id>
 </mixed-citation>
</ref>
